# Case Scenarios

## CASE 1

64-yr-old male w/ h/o HTN, DMII, who presented w/ cough, GERD. Pt reports dysphagia with solid foods, resulting in regurgitation. Former heavy smoker. Social etoh. +FHX: Sister w/ gastric cancer.

### Imaging:

6/17/22 @ YYY Hospital: EUS= 2.4 x 1.8 cm ill-defined mass @ EG junction.

6/20/22 @ YYY Hospital: CT chest= distention/dilation @ distal esophagus. No prominent lymphadenopathy noted.

6/28/22 @ YYY Hospital: Upper GI endoscopy= Z-line irregular, 35 cm from incisors. Biopsied. Sonographic evidence of extension into muscularis propria, but not beyond, Nodular mucosa in the gastric body. No gross lesion in the visualized duodenum.

7/20/22 @ YYY Hospital: PET/CT= increased FDG avidity in distal esophagus, GE junction. Small FDG avid upper abdominal lymph node consistent with metastatic disease.

### Pathology:

6/28/22 @ YYY Hospital: GE Junction Fine Needle Biopsy= poorly differentiated adenocarcinoma, with invasion into muscle. FNA= positive for malignant cells, favor adenocarcinoma.

Positive= CKY

Negative= CK20, CDX-2, p40. HER IHC= 1+, negative. MMR intact.

### Treatment:

8/20/22 @ ZZZ Hospital: Carboplatin + paclitaxel.

### Radiation Therapy Treatment Summary

**SUMMARY OF RADIATION FIELDS (ZZZ Hospital)**

### Course: 1

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Treatment Site** | **Ref. ID** | **Energy** | **Dose/Fx (cGy)** | **#Fx** | **Total Dose (cGy)** | **Start Date** | **End Date** | **Elapsed Days** |
| Esophagus/LN | Esophagus/LN | 6X | 180 | 19 / 19 | 3,420 | 8/15/2022 | 9/13/2022 | 29 |
| Eso/LN\_boost | Eso/LN boost | 6X | 180 | 9 / 9 | 1,620 | 9/15/2022 | 9/28/2022 | 13 |

####  Course: 1

Treatment Site: Esophagus/LN

Ref. ID: Esophagus/LN

Energy: 6X

Dose/Fx (cGy): 180

#Fx: 19 / 19

Dose Correction (cGy): 0

Total Dose (cGy): 3,420

Start Date: 8/15/2022

End Date: 9/13/2022

Elapsed Days: 29

#### Course: 1

Treatment Site: Eso/LN\_boost

Ref. ID: Eso/LN\_boost

Energy: 6X

Dose/Fx (cGy): 180

#Fx: 9 / 9

Dose Correction (cGy): 0

Total Dose (cGy): 1,620

Start Date: 9/15/2022

End Date: 9/28/2022

Elapsed Days: 13

**SUMMARY OF RADIATION TREATMENTS:** The patient was treated to the esophagus using a

**IMRT** technique. The patient tolerated treatments quite well. The patient had the expected side effects of esophagitis.





|  |
| --- |
| Case 1 Answer sheet |
| Primary Site |  | Grade Clinical |  |
| Histology |  | Grade Pathological |  |
| Behavior |  | yP Grade |  |
| Schema Discriminator 1 |  | Schema Discriminator 2 |  |
| HER 2 |  |  |  |
| Stage Data items |
| Clinical T |  | Pathological T |  | yP T |  |
| cT Suffix |  | pT Suffix |  | yP T Suffix |  |
| Clinical N |  | Pathological N |  | Yp N |  |
| cN Suffix |  | pN Suffix |  | yP N Suffix |  |
| Clinical M |  | Pathological M |  | yP M |  |
| Clinical Stage  |  | Pathological Stage |  | yP Stage |  |
|  | *Grade*  |
| Summary Stage 2018  |  |
| *EOD Primary Tumor* |  |
| *EOD Lymph Regional Nodes* |  |
| *EOD Mets* |  |

|  |
| --- |
| Radiation |
| Phases | **I** | **II** | **III** |
| Primary Treatment Volume |  |  |  |
| Draining Lymph Nodes |  |  |  |
| Treatment Modality |  |  |  |
| External Beam Planning Technique |  |  |  |
| Dose Per Fraction (cGy) |  |  |  |
| Number of Fractions |  |  |  |
| Total Dose (cGy) |  |  |  |
| Date RT Started |  |
| Date RT Ended |  |
| # of Phases of RT to this Volume |  |
| RT Discontinued Early |  |
| Total Dose |  |

## Case 2

74 y/o female with h/o GERD, HTN, HLD, DMII, who presented with difficulty with swallowing x 4 weeks. Pt also c/o chest pressure, choking, coughing, epigastric pain and weight loss. Former smoker. Social etoh. +FHX: Father with esophageal cancer.

### Imaging:

2/17/22 @ XXX Hospital:

**CT CAP**= Tiny 1-2 mm LUL pulmonary nodule, indeterminate. Abrupt circumferential luminal narrowing of lower half of esophagus inferior to the carina, approximately 28 cm from incisors, with 15 mm lobular lesion and an 8 mm nodule at 26 cm from incisors with diffuse nodularity at 32 cm from incisors.

Enlarged periesophageal, up to 1.5 cm, and upper abdominal lymphadenopathy, up to 4.5 cm, suspicious for metastases. No mediastinal or axillary lymphadenopathy. No suspicious lytic or blastic osseous lesions.

2/24/22 @ XXX Hospital:

Upper EUS: Esophageal mucosal changes classified as Barrett’s stage C9-M9, per Prague criteria. Findings suspicious for neoplasm. Erythematous mucosa without bleeding found in entire examined stomach.

2/28/22 @ ABC Radiology:

**PET/CT**= Hypermetabolic lower esophageal cancer with LT supraclavicular, mediastinal and upper abdominal nodal metastases (@ least 15 regional LN mets). Hypermetabolic focus without definite CT correlate overlying mid-esophageal wall.

No evidence for distant metastases.

### Pathology:

2/24/22 @ XXX Hospital: Esophagus bx

1. Esophagus bx @ 35 cm: poorly differentiated carcinoma with ulceration
2. Esophagus bx @ 33 cm: poorly differentiated carcinoma
3. Esophagus bx @ 31 cm: poorly differentiated carcinoma with ulceration, focal high grade dysplasia,
4. Esophagus bx @ 29 cm: poorly differentiated carcinoma with ulceration
5. Esophagus bx @ 27 cm: glandular mucosa with high grade dysplasia
6. Esophagus bx @ 25 cm: glandular epithelium with high grade dysplasia.

Oncosight Genpath panel positive for FGFR3>KLF15 gene fusion detected. Negative for ALK, AXL, BRAF, EGFR, FGFR1, MET, NRG1, NTRK1, RET, ROS1.

PD-L1 TPS= 50-60%.

MMR Intact. MSI stable. HER2 IHC= 3+, positive.

### Treatment:

3/21/22 @ XXX Hospital: Carboplatin + paclitaxel.

Radiation Therapy Treatment Summary (XXX Hospital)

**SUMMARY OF RADIATION FIELDS**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Treatment Site** | **Energy****Technique** | **Dose/Fx (cGy)** | **#Fx** | **Total Dose (cGy)** | **Start Date** | **End Date** |
| Plan\_Esophagus\_PTV\_5040 | 6X/IMRT | 180 | 28 / 28 | 5,040 | 03/21/2022 | 04/27/2022 |





|  |
| --- |
| Case 2 Answer sheet |
| Primary Site |  | Grade Clinical |  |
| Histology |  | Grade Pathological |  |
| Behavior |  | Grade Post Therapy |  |
| Schema Discriminator 1 |  | Schema Discriminator 2 |  |
| Her 2 |  |  |  |
| Stage Data items |
| Clinical T |  | Pathological T |  | yP T |  |
| cT Suffix |  | pT Suffix |  | yP T Suffix |  |
| Clinical N |  | Pathological N |  | Yp N |  |
| cN Suffix |  | pN Suffix |  | yP N Suffix |  |
| Clinical M |  | Pathological M |  | yP M |  |
| Clinical Stage  |  | Pathological Stage |  | yP Stage |  |
|  | *Grade* |
| Summary Stage 2018  |  |
| *EOD Primary Tumor* |  |
| *EOD Lymph Regional Nodes* |  |
| *EOD Mets* |  |

|  |
| --- |
| Radiation |
| Phases | **I** | **II** | **III** |
| Primary Treatment Volume |  |  |  |
| Draining Lymph Nodes |  |  |  |
| Treatment Modality |  |  |  |
| External Beam Planning Technique |  |  |  |
| Dose Per Fraction (cGy) |  |  |  |
| Number of Fractions |  |  |  |
| Total Dose (cGy) |  |  |  |
| Date RT Started |  |
| Date RT Ended |  |
| # of Phases of RT to this Volume |  |
| RT Discontinued Early |  |
| Total Dose |  |

## Case 3:

79 yr-old Caucasian male with h/o HTN, HLD, DMII, COPD, significant smoking hx (30 Pk-Yr), who presented with anemia and chest discomfort. Former etoh abuse (sober since 2010). -fhx.

### Scope:

5/16/22 @ XXX Medical Ctr:

Upper EUS= Likely malignant esophageal tumor at GE junction, extending into gastric cardia. Biopsied. Mass found in the GE junction. This was staged T2 N1 by endosonographic criteria using the esophagus staging protocol. In addition, two malignant-appearing lymph nodes were visualized in the perigastric region. FNB performed from the largest node measuring 11 mm.

### Imaging:

06/06/22 @ YYY Hospital: CT CAP= Soft tissue thickening within the superior stomach/GE junction, most likely representing pt’s known esophageal carcinoma. Adjacent perigastric lymph node noted. Metastatic lymph node not excluded. No evidence of metastatic disease within pelvis.

06/14/22 @ YYY Hospital: PET/CT= Hypermetabolic distal esophageal lesion consistent with esophageal cancer. Abnormal thickening superior stomach and GE junction, SUV max 5.5. Mildly prominent medial perigastric lymph nodes with mild uptake. Could represent inflammation or potentially metastatic lymph node. No other abnormal metabolic activity noted.

### Pathology:

5/16/22 @ XXX Medical Ctr:

1. GE Junction bx= invasive moderately differentiated adenocarcinoma with mucinous features.
2. Peri-gastric lymph node FNB= metastatic moderately differentiated adenocarcinoma.

HER2 IHC= 1+, negative. MMR panel intact.

5/16/22 @ XXX Medical Ctr:

* Peri-gastric lymph node Ultrasound-guided FNA= positive for malignancy. Metastatic adenocarcinoma. Cytologic findings correlate with patient’s concurrent pathologic specimen.

### Treatment:

07/22/22 @ XXX Hospital: Carboplatin + paclitaxel weekly x 8 cycles.

Radiation Therapy Treatment Summary @ XXX Hospital:

**SUMMARY OF RADIATION FIELDS**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Treatment Site** | **Energy****Technique** | **Dose/Fx (cGy)** | **#Fx** | **Total Dose (cGy)** | **Start Date** | **End Date** |
| Plan\_Esophagus\_PTV\_5040 | 6X/IMRT | 180 | 28 / 28 | 5,040 | 07/22/2022 | 08/30/2022 |

****

|  |
| --- |
| Case 3 Answer sheet |
| Primary Site |  | Grade Clinical |  |
| Histology |  | Grade Pathological |  |
| Behavior |  | Grade Post Therapy |  |
| Schema Discriminator 1 |  | Schema Discriminator 2 |  |
| Her 2 |  |  |  |
| Stage Data items |
| Clinical T |  | Pathological T |  | yP T |  |
| cT Suffix |  | pT Suffix |  | yP T Suffix |  |
| Clinical N |  | Pathological N |  | Yp N |  |
| cN Suffix |  | pN Suffix |  | yP N Suffix |  |
| Clinical M |  | Pathological M |  | yP M |  |
| Clinical Stage  |  | Pathological Stage |  | yP Stage |  |
|  |  |
| Summary Stage 2018  |  |
| *EOD Primary Tumor* |  |
| *EOD Lymph Regional Nodes* |  |
| *EOD Mets* |  |

|  |
| --- |
| Radiation |
| Phases | **I** | **II** | **III** |
| Primary Treatment Volume |  |  |  |
| Draining Lymph Nodes |  |  |  |
| Treatment Modality |  |  |  |
| External Beam Planning Technique |  |  |  |
| Dose Per Fraction (cGy) |  |  |  |
| Number of Fractions |  |  |  |
| Total Dose (cGy) |  |  |  |
| Date RT Started |  |
| Date RT Ended |  |
| # of Phases of RT to this Volume |  |
| RT Discontinued Early |  |
| Total Dose |  |

## Case 4:

45 y/o Caucasian male who presented to his PCP with hoarseness, dysphagia and chest pressure when eating. Patient reports a 15 lb weight loss in past 3 months. Former smoker. Social etoh. +fhx: father w/ prostate cancer at 74.

Pt opted for neoadjuvant chemo/RT, followed by surgery.

### Scope:

4/5/22 @ YYY Hospital:

**Upper EUS**: Submucosal mass @ GEJ extending into the gastric cardia at the proximal lesser curvature. Mass extends from 43 to 47 cm. Mass is not obstructing. Sonographically, T3, N0.

### Imaging:

4/11/22 @ YYY Hospital:

**CT CAP**= Non-specific small right upper lobe reticulonodular densities, likely infectious/inflammatory in etiology. No mediastinal lymphadenopathy noted. Recommend CT f/u in 3 months.

Non-specific mild thickening of the gastroesophageal junction in the region of clinically known lesion. No evidence of metastatic disease. No evidence of significant retroperitoneal or pelvic lymphadenopathy.

### Pathology:

4/5/22 @ YYY Hospital: EG Junction bx; adenocarcinoma. Reviewed @ XXX Hospital on 4/10/22, which read specimen as moderately to poorly differentiated adenocarcinoma.

8/9/22 @ XXX Hospital: Laparoscopic esophagectomy with regional lymph node dissection.

* foci of residual adenocarcinoma invading esophageal wall and paraesophageal fat.
* LVI negative.
* Regional lymph nodes examined= 22
* Regional lymph nodes with micromets= 0
* Regional lymph nodes with macromets= 0.

### Treatment:

4/26/22 @ XXX Hospital: Carboplatin + paclitaxel x 8 cycles.

Radiation Therapy Treatment Summary @ XXX Hospital:

**SUMMARY OF RADIATION FIELDS**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Treatment Site** | **Energy****Technique** | **Dose/Fx (cGy)** | **#Fx** | **Total Dose (cGy)** | **Start Date** | **End Date** |
| Plan\_Esophagus\_PTV\_5040 | 6X/IMRT | 180 | 28 / 28 | 5,040 | 04/26/2022 | 05/02/2022 |

|  |
| --- |
| Case 4 Answer sheet |
| Primary Site |  | Grade Clinical |  |
| Histology |  | Grade Pathological |  |
| Behavior |  | Grade Pathological Post Therapy |  |
| Schema Discriminator 1 |  | Schema Discriminator 2 |  |
| Stage Data items |
| Clinical T |  | Pathological T |  | yp T |  |
| cT Suffix |  | pT Suffix |  | yp T Suffix |  |
| Clinical N |  | Pathological N |  | yp N |  |
| cN Suffix |  | pN Suffix |  | yp N Suffix |  |
| Clinical M |  | Pathological M |  | yp M |  |
| Clinical Stage  |  | Pathological Stage |  | yp Stage |  |
|  | *Grade*  |
| Summary Stage 2018  |  |
| *EOD Primary Tumor* |  |
| *EOD Lymph Regional Nodes* |  |
| *EOD Mets* |  |

|  |
| --- |
| Radiation |
| Phases | **I** | **II** | **III** |
| Primary Treatment Volume |  |  |  |
| Draining Lymph Nodes |  |  |  |
| Treatment Modality |  |  |  |
| External Beam Planning Technique |  |  |  |
| Dose Per Fraction (cGy) |  |  |  |
| Number of Fractions |  |  |  |
| Total Dose (cGy) |  |  |  |
| Date RT Started |  |
| Date RT Ended |  |
| # of Phases of RT to this Volume |  |
| RT Discontinued Early |  |
| Total Dose |  |